Advancing mRNA-based drug development and vaccine manufacturing
Shared by Parexel experts, Christiane Niederlaender, Cecil Nick, and Sinan Sarac covering on the topics of:
Section 1 - Overview of mRNA Product Manufacturing Challenges
Section 2 - Optimizing the Path to Regulatory Approval for Novel Vaccine
Section 3 - Accelerating Approval of mRNA vaccines for Oncology Drug development
Related Insights
Blog
Navigating the path to conditional approval: avoiding pitfalls in oncology drug applications
Feb 4, 2025
Blog
PD-1 inhibitors face scrutiny in esophageal cancer: Key takeaways for drug developers
Oct 4, 2024
Article
Five strategies for meeting the requirements of Project Optimus and improving the chances of approval
Nov 10, 2022
Article
Q&A Project Optimus: What you need to know
Oct 11, 2022
Blog
Making cell and gene therapy more accessible in the treatment of solid tumors
Jun 4, 2024
Webinar
Challenges and best practices for developing Antibody-Drug Conjugates (ADCs)
Nov 12, 2024
Webinar
Accelerating delivery of radiopharmaceutical trials
Oct 3, 2025
Blog
New EU pharmaceutical legislation: Strategic implications for drug developers
Feb 17, 2026
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Webinar
Breakthrough Devices Program: Where’s the value?
Nov 13, 2023
Whitepaper
Advancing clinical development through innovative trial design
Nov 3, 2023
Blog
Assessing the need for comparative clinical trials in biosimilar development programs
Sep 21, 2023
Related Insights
Blog
Navigating the path to conditional approval: avoiding pitfalls in oncology drug applications
Feb 4, 2025
Blog
PD-1 inhibitors face scrutiny in esophageal cancer: Key takeaways for drug developers
Oct 4, 2024
Article
Five strategies for meeting the requirements of Project Optimus and improving the chances of approval
Nov 10, 2022
Article
Q&A Project Optimus: What you need to know
Oct 11, 2022
Blog
Making cell and gene therapy more accessible in the treatment of solid tumors
Jun 4, 2024
Webinar
Challenges and best practices for developing Antibody-Drug Conjugates (ADCs)
Nov 12, 2024
Webinar
Accelerating delivery of radiopharmaceutical trials
Oct 3, 2025
Blog
New EU pharmaceutical legislation: Strategic implications for drug developers
Feb 17, 2026
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Webinar
Breakthrough Devices Program: Where’s the value?
Nov 13, 2023
Whitepaper
Advancing clinical development through innovative trial design
Nov 3, 2023
Blog
Assessing the need for comparative clinical trials in biosimilar development programs
Sep 21, 2023